Article
Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors.
Molecular cancer research : MCR - 2 May 2025
Cuellar-Vite Leslie, Donaubauer Elyse M, Weber-Bonk Kristen L, Bobbitt Jessica R, Ingles Natasha N, Brzozowski Taylor L, Abdul-Karim Fadi W, Booth Christine N, Keri Ruth A
Abstract excerpt
EGFR is a highly expressed driver of many cancers, yet the utility of EGFR inhibitors (EGFRi) is limited to cancers that harbor sensitizing mutations in the EGFR gene because of dose-limiting toxicities. Rather than conventionally blocking the kinase activity of EGFR, we sought to reduce its transcription as an alternative approach to broaden the therapeutic window for EGFR inhibitors targeting wild-type (WT) or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.